On April 20, at the 2026 American Academy of Neurology (AAN) meeting, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel (resecabtagene autoleucel) in patients with generalised myasthenia gravis (gMG) (NCT06359041). The study sought to evaluate the efficacy and safety of rese-cel in adult participants with acetylcholine receptor binding antibody seropositive (AChR+), muscle-specific tyrosine kinase seropositive (Musk+), low-density lipoprotein receptor-related protein 4 seropositive (LRP4+), or triple seronegative gMG. This means that rese-cel may one day have the potential to challenge all currently marketed disease-modifying therapies (DMTs) for MG. With that being said, the existing DMTs are highly effective, and other cell therapies in the late-stage pipeline may look to occupy a similar positioning, so rese-cel will have to differentiate itself in a crowded MG market to gain traction.
Rese-cel is an investigational chimeric antigen receptor (CAR-T) cell therapy designed to treat MG by targeting the B cells that mediate the disease. MG is characterised by pathogenic autoantibodies—produced by B cells—that target proteins operating at the neuromuscular junction (usually acetylcholine receptors), leading to skeletal muscle weakness. RESET-MG is a Phase I/II, open-label study of rese-cel in gMG. Patients were enrolled in two cohorts, AChR+ and AChR- (composed of Musk+, LRP4+, and triple seronegative patients), with seven patients in the AChR+ arm and six patients in the AChR- arm. The primary endpoint was the incidence and severity of adverse events. The trial met its primary endpoint, with the treatment appearing to be generally well-tolerated. No cytokine release syndrome (CRS), a common side effect of CAR-T cell therapies, was observed in 11 of the 13 patients enrolled in the study. Of the two patients who experienced CRS, the CRS was mild and resolved with no sequelae. Furthermore, no immune effector cell-associated neurotoxicity syndrome (ICANS), another side effect associated with CAR-T cell therapies, was observed in either cohort. The secondary endpoints included efficacy measures such as Myasthenia Gravis Activities of Daily Living (MG-ADL), which were also promising, with five AChR+ patients showing clinically meaningful improvements in the MG-ADL scale, and five AChR- patients also showing clinically meaningful improvements. The results were promising, as the trial’s primary endpoint was achieved and the treatment appeared to be generally safe and showed early efficacy signals. This indicates that rese-cel is poised to move onto Phase IIb trials, as the company looks to advance its MG development.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
As a DMT, rese-cel would be entering a highly competitive space in the market, as there are several DMTs targeting the different subtypes of MG. According to GlobalData’s drugs database, there are eight DMTs currently marketed across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) for MG. Key opinion leaders (KOLs) previously interviewed by GlobalData have stated that any DMT entering the market would have to display efficacy over existing treatments, as there are well-entrenched therapies available for MG patients. One way in which Cabaletta Bio could differentiate rese-cel from the competition is by targeting marginalised patient groups. The RESET-MG trial sought to recruit patients who were LRP4+ and triple seronegative, which is important as KOLs interviewed by GlobalData have noted that there is a significant unmet need for effective treatments targeting the LRP4+ seronegative patient populations. There currently is no effective DMT on the market targeting these MG populations, meaning that Cabaletta Bio can position rese-cel to meet this unmet need. KOLs have also noted that previous studies involving CAR-T cell therapies have been small, so their wider applicability is not yet known, given the significant safety risks associated with taking the therapy, and that CAR-T therapies will likely be reserved for later on in the treatment algorithm should other therapies fail. This means that Cabaletta Bio should position rese-cel in a marginalised patient population, such as the LRP4+ or triple seronegative patients, where it is most likely to occupy a niche and make an impact.
The Phase I/II clinical trial results for rese-cel are promising and likely to act as a strong base from which to develop the therapy further in Phase IIb trials. However, Cabaletta Bio faces challenges as it is potentially entering a highly competitive market filled with established DMTs and must ensure that it differentiates rese-cel from marketed drugs and pipeline cell therapies. Rese-cel has the potential to become a valuable addition to the gMG treatment paradigm, offering new possibilities for disease management, should Cabaletta Bio be able to successfully navigate the complexities of market competition.
